Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins

Cancer Gene Therapy volume 9, pages 884–896 (2002)Cite this article

Abstract

Although several clinical trials have shown beneficial effects by targeting tumor-associated antigens (TAAs) with monoclonal antibodies, a number of issues, including poor penetration of the tumor mass and human antimouse antibody responses, remain. The use of recombinant single-chain Fv (scFv) fragments has the potential to address these and other issues while allowing the addition of different effector functions. To develop therapeutic strategies that recruit both humoral and cellular arms of the immune response, we have constructed chimeric proteins linking either the human IgG1 Fc domain or the extracellular domain of murine B7.1 to a scFv specific for the oncofetal glycoprotein, 5T4. This TAA is expressed by a wide variety of carcinomas and is associated with metastasis and poorer clinical outcome. We have engineered retroviral constructs that produce fusion proteins able to interact simultaneously with both 5T4-positive cells and with the receptor/ligands of the immune effector moieties. Genetic delivery through a murine leukemia virus vector to 5T4-positive tumor cells results in the secreted scFv fusion protein binding to the cell surface. Furthermore, the scFv–HIgG1 fusion protein is able to direct lysis of 5T4-expressing human tumor cell lines through antibody-dependent cell cytotoxicity, indicating its potential as a gene therapy for human cancers.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10

Similar content being viewed by others

References

  1. Durrant LG, Maxwell-Armstrong C, Buckley D et al. A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55 Clin Cancer Res 2000 6: 422–430

    CAS  PubMed  Google Scholar 

  2. Foran JM, Rohatiner AZ, Cunningham D et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma J Clin Oncol 2000 18: 317–324

    Article  CAS  PubMed  Google Scholar 

  3. Riethmuller G, Holz E, Schlimok G et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial J Clin Oncol 1998 16: 1788–1794

    Article  CAS  PubMed  Google Scholar 

  4. Divgi CR, Scott AM, Dantis L et al. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma J Nucl Med 1995 36: 586–592

    CAS  PubMed  Google Scholar 

  5. Zeng ZC, Tang ZY, Liu KD, Lu JZ, Xie H, Yao Z . Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131I–anti-HCC mAb. Phase I/II clinical trials J Cancer Res Clin Oncol 1998 124: 275–280

    Article  CAS  PubMed  Google Scholar 

  6. Appelbaum FR . Antibody-targeted therapy for myeloid leukemia Semin Hematol 1999 36: 2–8

    CAS  PubMed  Google Scholar 

  7. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA . Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) Semin Oncol 1999 26: 60–70

    CAS  PubMed  Google Scholar 

  8. Tse E, Rabbitts TH . Intracellular antibody-caspase–mediated cell killing: an approach for application in cancer therapy Proc Natl Acad Sci USA 2000 97: 12266–12271

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Gutheil JC, Campbell TN, Pierce PR et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3 Clin Cancer Res 2000 6: 3056–3061

    CAS  PubMed  Google Scholar 

  10. Vollmers HP, Zimmermann U, Krenn V et al. Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results Oncol Rep 1998 5: 549–552

    CAS  PubMed  Google Scholar 

  11. Cooley S, Burns LJ, Repka T, Miller JS . Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu Exp Hematol 1999 27: 1533–1541

    Article  CAS  PubMed  Google Scholar 

  12. Grillo-Lopez AJ, White CA, Varns C et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma Semin Oncol 1999 26: 66–73

    CAS  PubMed  Google Scholar 

  13. Sharkey RM, Gold DV, Aninipot R et al. Comparison of tumor targeting in nude mice by murine monoclonal antibodies directed against different human colorectal cancer antigens Cancer Res 1990 50: 828s–834s

    CAS  PubMed  Google Scholar 

  14. Yokota T, Milenic DE, Whitlow M, Schlom J . Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms Cancer Res 1992 52: 3402–3408

    CAS  PubMed  Google Scholar 

  15. Khazaeli MB, Conry RM, LoBuglio AF . Human immune response to monoclonal antibodies J Immunother 1994 15: 42–52

    Article  CAS  Google Scholar 

  16. Adams GP, McCartney JE, Tai MS et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti–c-erbB-2 single-chain Fv Cancer Res 1993 53: 4026–4034

    CAS  PubMed  Google Scholar 

  17. Milenic DE, Yokota T, Filpula DR et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49 Cancer Res 1991 51: 6363–6371

    CAS  PubMed  Google Scholar 

  18. Clark MR . IgG effector mechanisms Chem Immunol 1997 65: 88–110

    Article  CAS  PubMed  Google Scholar 

  19. Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM . The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response Immunol Rev 1996 153: 5–26

    Article  CAS  PubMed  Google Scholar 

  20. Griffiths L, Binley K, Iqball S et al. The macrophage — a novel system to deliver gene therapy to pathological hypoxia Gene Ther 2000 7: 255–262

    Article  CAS  PubMed  Google Scholar 

  21. Whittington HA, Ashworth LJ, Hawkins RE . Recombinant adenoviral delivery for in vivo expression of scFv antibody fusion proteins Gene Ther 1998 5: 770–777

    Article  CAS  PubMed  Google Scholar 

  22. Hu Z, Garen A . Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy Proc Natl Acad Sci USA 2000 97: 9221–9225

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Cochet O, Kenigsberg M, Delumeau I et al. Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression Cancer Res 1998 58: 1170–1176

    CAS  PubMed  Google Scholar 

  24. Myers KA, Rahi-Saund V, Davison MD, Young JA, Cheater AJ, Stern PL . Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein. An antigen associated with metastasis contains leucine-rich repeats J Biol Chem 1994 269: 9319–9324

    CAS  PubMed  Google Scholar 

  25. Hole N, Stern PL . A 72 kD trophoblast glycoprotein defined by a monoclonal antibody Br J Cancer 1988 57: 239–246

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Hole N, Stern PL . Isolation and characterization of 5T4, a tumour-associated antigen Int J Cancer 1990 45: 179–184

    Article  CAS  PubMed  Google Scholar 

  27. Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley M, Stern PL . Immunohistological distribution of 5T4 antigen in normal and malignant tissues Br J Cancer 1990 61: 89–95

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Jones H, Roberts G, Hole N, McDicken IW, Stern P . Investigation of expression of 5T4 antigen in cervical cancer Br J Cancer 1990 61: 96–100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Wrigley E, McGown A, Rennison J et al. 5T4 oncofetal antigen expression in ovarian carcinoma Int J Gynecol Cancer 1995 5: 269–274

    Article  PubMed  Google Scholar 

  30. Starzynska T, Rahi V, Stern PL . The expression of 5T4 antigen in colorectal and gastric carcinoma Br J Cancer 1992 66: 867–869

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Starzynska T, Marsh PJ, Schofield PF, Roberts SA, Myers KA, Stern PL . Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma Br J Cancer 1994 69: 899–902

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Forsberg G, Ohlsson L, Brodin T et al. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen Br J Cancer 2001 85: 129–136

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Shaw DM, Embleton MJ, Westwater C et al. Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4 Biochim Biophys Acta 2000 1524: 238–246

    Article  CAS  PubMed  Google Scholar 

  34. Landau NR, Littman DR . Packaging system for rapid production of murine leukemia virus vectors with variable tropism J Virol 1992 66: 5110–5113

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Soneoka Y, Cannon PM, Ramsdale EE et al. A transient three-plasmid expression system for the production of high titer retroviral vectors Nucleic Acids Res 1995 23: 628–633

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Nambu M, Morita M, Watanabe H et al. Regulation of Fc gamma receptor expression and phagocytosis of a human monoblast cell line U937. Participation of cAMP and protein kinase C in the effects of IFN-gamma and phorbol ester J Immunol 1989 143: 4158–4165

    CAS  PubMed  Google Scholar 

  37. Primus FJ, Finch MD, Masci AM, Schlom J, Kashmiri SV . Self-reactive antibody expression by human carcinoma cells engineered with monoclonal antibody genes Cancer Res 1993 53: 3355–3361

    CAS  PubMed  Google Scholar 

  38. Roovers RC, Henderikx P, Helfrich W et al. High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting Br J Cancer 1998 78: 1407–1416

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Velders MP, van Rhijn CM, Oskam E, Fleuren GJ, Warnaar SO, Litvinov SV . The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas Br J Cancer 1998 78: 478–483

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Townsend SE, Allison JP . Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells Science 1993 259: 368–370

    Article  CAS  PubMed  Google Scholar 

  41. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH . Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules Proc Natl Acad Sci USA 1993 90: 5687–5690

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Chen L, McGowan P, Ashe S et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell–mediated tumor immunity J Exp Med 1994 179: 523–532

    Article  CAS  PubMed  Google Scholar 

  43. Carroll MW, Overwijk WW, Surman DR, Tsung K, Moss B, Restifo NP . Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen J Natl Cancer Inst 1998 90: 1881–1887

    Article  CAS  PubMed  Google Scholar 

  44. Gilligan MG, Knox P, Weedon S et al. Adenoviral delivery of B7-1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells Gene Ther 1998 5: 965–974

    Article  CAS  PubMed  Google Scholar 

  45. Holliger P, Manzke O, Span M et al. Carcinoembryonic antigen (CEA)–specific T-cell activation in colon carcinoma induced by anti-CD3×anti-CEA bispecific diabodies and B7×anti-CEA bispecific fusion proteins Cancer Res 1999 59: 2909–2916

    CAS  PubMed  Google Scholar 

  46. Ragnhammar P, Frodin J-E, Hjelm A-L et al. Different dose regimens of the mouse monoclonal antibody 17-1A for therapy of patients with metastatic colorectal carcinoma Int J Oncol 1995 7: 1049–1056

    CAS  PubMed  Google Scholar 

  47. Juweid ME, Hajjar G, Swayne LC et al. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma Cancer 1999 85: 1828–1842

    Article  CAS  PubMed  Google Scholar 

  48. LoBuglio AF, Wheeler RH, Trang J et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response Proc Natl Acad Sci USA 1989 86: 4220–4224

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Gruber R, van Haarlem LJ, Warnaar SO, Holz E, Riethmuller G . The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A Cancer Res 2000 60: 1921–1926

    CAS  PubMed  Google Scholar 

  50. Clark JI, Alpaugh RK, von Mehren M et al. Induction of multiple anti–c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment Cancer Immunol Immunother 1997 44: 265–272

    Article  CAS  PubMed  Google Scholar 

  51. Sacchi S, Federico M, Dastoli G et al. Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab Crit Rev Oncol Hematol 2001 37: 13–25

    Article  CAS  PubMed  Google Scholar 

  52. Huls GA, Heijnen IA, Cuomo ME et al. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments Nat Biotechnol 1999 17: 276–281

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oxford BioMedica (UK) Ltd., Medawar Centre, Oxford Science Park, Oxford, UK

    Kevin A Myers, Matthew G Ryan, Susan M Kingsman & Miles W Carroll

  2. Immunology Department, Paterson Institute For Cancer Research, Christie Hospital, Manchester, UK

    Peter L Stern & David M Shaw

  3. Medical Oncology, Paterson Institute For Cancer Research, Christie Hospital, Manchester, UK

    M Jim Embleton

Authors
  1. Kevin A Myers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew G Ryan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter L Stern
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David M Shaw
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Jim Embleton
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Susan M Kingsman
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Miles W Carroll
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Miles W Carroll.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Myers, K., Ryan, M., Stern, P. et al. Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins. Cancer Gene Ther 9, 884–896 (2002). https://doi.org/10.1038/sj.cgt.7700513

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700513

Keywords

This article is cited by

Search

Advanced search

Quick links